DCF Valuation
NewGenIvf Group Limited Class A Ordinary Shares (NIVF) DCF Valuation — Is NIVF undervalued?
The estimated DCF fair value of one NewGenIvf Group Limited Class A Ordinary Shares (NIVF) share is $3.91. Compared to the current market price of $0.62, the stock is undervalued by 530.3%.
DCF fair value
$3.91
Market price
$0.62
Upside / downside
+530.3%
Prefer the inverse question? See what growth rate the market is pricing into NIVF →
NewGenIvf Group Limited Class A Ordinary Shares (NIVF) DCF valuation FAQ
What is the DCF fair value of NewGenIvf Group Limited Class A Ordinary Shares (NIVF)?
The discounted-cash-flow model estimates the intrinsic fair value of one NewGenIvf Group Limited Class A Ordinary Shares (NIVF) share at $3.91, based on a 10-year projection of its cash flows converging to Damodaran industry averages.
Is NewGenIvf Group Limited Class A Ordinary Shares (NIVF) overvalued or undervalued?
Against the current market price of $0.62, the DCF fair value of $3.91 implies NIVF is undervalued by 530.3%.
How is the NIVF DCF value calculated?
It is a 10-year discounted-cash-flow estimate built from NewGenIvf Group Limited Class A Ordinary Shares's reported fundamentals, with terminal assumptions anchored to Damodaran NYU industry datasets. The market price refreshes daily; the DCF fair value updates when NewGenIvf Group Limited Class A Ordinary Shares files a new quarterly or annual report.
How this NIVF valuation is built
The model projects ten years of NewGenIvf Group Limited Class A Ordinary Shares's free cash flow to the firm and discounts each year at its own cost of capital. Rather than assuming today's growth and margins persist forever, a moat-scoring step — weighing NewGenIvf Group Limited Class A Ordinary Shares's ROIC-versus-WACC spread, gross-margin trend, and reinvestment efficiency — decides how many years the business holds its edge before its economics mean-revert toward the Damodaran NYU benchmarks for its industry.
WACC is rebuilt each year from an unlevered-then-relevered beta and the company's evolving capital structure; terminal value uses the Gordon growth model with a reinvestment rate tied to the return earned on new capital (goodwill stripped out to reflect operating efficiency). Every assumption — growth, margins, tax, leverage, convergence timing — is editable, and running the full interactive model adds a 10,000-draw Monte Carlo simulation and WACC-versus-terminal-growth sensitivity heatmaps.
The market price refreshes daily; the DCF fair value updates when NewGenIvf Group Limited Class A Ordinary Shares files a new quarterly or annual report. For educational/informational purposes only — not investment advice. Last updated 2026-08-06.